ProMIS Historical Income Statement
| PMN Stock | USD 0.94 0.02 2.17% |
Historical analysis of ProMIS Neurosciences income statement accounts such as Research Development of 4.3 M, Total Operating Expenses of 6.1 M, Total Other Income Expense Net of 1.4 M or Selling General Administrative of 7.8 M can show how well ProMIS Neurosciences performed in making a profits. Evaluating ProMIS Neurosciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ProMIS Neurosciences's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining ProMIS Neurosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ProMIS Neurosciences is a good buy for the upcoming year.
ProMIS |
About ProMIS Income Statement Analysis
ProMIS Neurosciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ProMIS Neurosciences shareholders. The income statement also shows ProMIS investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
ProMIS Neurosciences Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ProMIS Neurosciences. It is also known as ProMIS Neurosciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from ProMIS Neurosciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ProMIS Neurosciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.At this time, ProMIS Neurosciences' Depreciation And Amortization is very stable compared to the past year. As of the 30th of November 2024, Other Operating Expenses is likely to grow to about 19.8 M, while Interest Expense is likely to drop about 191.3 K.
| 2021 | 2023 | 2024 (projected) | Cost Of Revenue | 5.9M | 10.4M | 11.3M | Interest Income | 4.7K | 5.4K | 5.7K |
ProMIS Neurosciences income statement Correlations
Click cells to compare fundamentals
ProMIS Neurosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ProMIS Neurosciences income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 6.6K | 12.3K | 45.8K | 15.2K | 28.0K | 46.1K | |
| Total Revenue | 7.9K | 348.74 | 920.18 | 1.4K | 8.1K | 0.0 | |
| Gross Profit | 920.18 | (3.2M) | (5.8M) | (21.8M) | (10.4M) | (9.9M) | |
| Other Operating Expenses | 5.7M | 4.4M | 8.3M | 23.4M | 18.9M | 19.8M | |
| Operating Income | (5.7M) | (4.4M) | (8.2M) | (23.4M) | (18.9M) | (18.0M) | |
| Ebit | (5.7M) | (4.4M) | (9.4M) | (29.9M) | (17.8M) | (16.9M) | |
| Research Development | 3.6M | 2.5M | 4.9M | 16.1M | 7.9M | 4.3M | |
| Ebitda | (5.7M) | (4.4M) | (9.3M) | (29.9M) | (17.8M) | (16.9M) | |
| Total Operating Expenses | 5.7M | 4.4M | 8.3M | 23.4M | 8.5M | 6.1M | |
| Income Before Tax | (5.7M) | (4.4M) | (9.2M) | (18.1M) | (17.5M) | (16.6M) | |
| Net Income | (5.7M) | (4.4M) | (9.7M) | (12.7M) | (17.5M) | (16.6M) | |
| Selling General Administrative | 2.0M | 1.9M | 3.3M | 7.3M | 7.4M | 7.8M | |
| Net Income From Continuing Ops | (5.7M) | (4.4M) | (9.2M) | (18.1M) | (16.9M) | (16.1M) | |
| Reconciled Depreciation | 6.6K | 12.3K | 45.7K | 11.2K | 4.7K | 4.5K | |
| Net Income Applicable To Common Shares | (7.4M) | (5.7M) | (11.8M) | (18.1M) | (16.3M) | (17.1M) |
Pair Trading with ProMIS Neurosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProMIS Neurosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProMIS Neurosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with ProMIS Stock
Moving against ProMIS Stock
| 0.83 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.81 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.77 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.77 | GILD | Gilead Sciences | PairCorr |
| 0.68 | EBS | Emergent Biosolutions | PairCorr |
The ability to find closely correlated positions to ProMIS Neurosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProMIS Neurosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProMIS Neurosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProMIS Neurosciences to buy it.
The correlation of ProMIS Neurosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProMIS Neurosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProMIS Neurosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProMIS Neurosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.04 | Revenue Per Share 0.001 | Return On Assets (4.81) | Return On Equity (10.99) |
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.